2021年3月10日
SOMERSET, N.J., March 10, 2021 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will release its fourth quarter and full-year 2020 financial results before U.S. financial markets open on Thursday, March 18, 2021.
Legend Biotech will conduct a conference call to discuss those results on March 18, 2021 at 8:00 am ET. To listen to the call via webcast visit Legend Biotech’s website at https://investors.legendbiotech.com/events-and-presentations. To listen to the call via telephone dial (833) 665-0666 from locations in the United States or (914) 987-7318 from outside the United States. Please refer to conference ID number 2677312. A replay of the webcast will be available on the “Events and Presentations” page within the Investors section of the website at https://investors.legendbiotech.com/events-andpresentations for 90 days following the conference call.
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 800 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture cutting edge cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, ciltacabtagene autoleucel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.
To learn more about Legend Biotech, visit us on LinkedIn, or on Twitter @LegendBiotechor at www.legendbiotech.com.
For Media and Investor Relations inquiries, please contact:
Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech jessie.yeung@legendbiotech.com or investor@legendbiotech.com
欧盟委员会批准 CARVYKTI®用于复发和难治性多发性骨髓瘤患者的二线..
2024年4月23日
传奇生物CARVYKTI®成为首个且唯一获FDA批准用于多发性骨髓瘤二线治..
2024年4月5日
传奇生物发布首份环境、社会和管治(ESG)报告
2024年3月19日
CARVYKTI®获得美国FDA肿瘤药物咨询委员会用于复发或难治性多发性骨..
2024年3月16日
传奇生物公布2023年全年及第四季度业绩及近期亮点
2024年3月11日
传奇生物获得CHMP对CARVYKTI®用于前线治疗的积极意见
2024年2月23日